Navigation Links
Cellectar Completes Enrollment in Phase I Clinical Trial of Lead Drug Candidate (131)I-CLR1404 for the Treatment of Solid Malignancies
Date:3/9/2010

MADISON, Wis., March 9 /PRNewswire/ -- Cellectar, Inc., a privately held radiopharmaceutical company that designs and develops products to detect, treat and monitor human cancers, today announced that enrollment for its Phase I dosimetry trial for its lead drug candidate, (131)I-CLR1404 has been completed. Results of this trial will be used to set the starting dose in a follow-on Phase I dose escalation study planned for later this year. Institutions that participated in the trial include City of Hope, Duke University Medical Center, Georgetown University/Lombardi Cancer Center, and Johns Hopkins Hospital.  

Eight patients with advanced solid malignancies were enrolled in the trial which was designed to measure drug safety and the normal organ and whole body dosimetry of (131)I-CLR1404. Dosimetry measurements allow investigators to understand how the radiopharmaceutical will impact non-tumor organs and how it clears from the body over time. Results will be used to set the starting dose for the second Phase I study – a dose escalation study to determine the Maximum Tolerated Dose (MTD) of (131)I-CLR1404 in patients with advanced solid malignancies.

Lead investigator Joanne Mortimer, MD, Vice Chair of Medical Oncology & Therapeutics Research, City of Hope, said, "This drug candidate has the potential to treat many tumor types, including some of the most challenging. The results of this initial study will provide a better understanding of the full potential of (131)I-CLR1404 and, enable us to move forward toward determining an appropriate therapeutic dose for patients."

Cellectar's President and CEO, Bill Clarke, M.D., commented, "The dosimetry and biodistribution results of this study reveal both the initial safety profile of this drug and an approximate possible dose range that a patient could receive in a therapeutic situation. We look forward to continuing the development of (131)I-CLR1404 in order to determine the safe dose, and then to begin our efficacy studies. Having the opportunity to assess the potential of (131)I-CLR1404 therapy for solid tumor patients who have few treatment options is our primary goal."

About (131)I-CLR1404

Cellectar's (131)I-CLR1404 is a small-molecule, phospholipid ether analog that combines lipid-like properties with a cancer therapeutic beta-emitting radioisotope. Cellectar believes that this compound will benefit individuals with cancer due to its selective retention and accumulation in malignant cells versus nonmalignant cells. Preclinical animal studies demonstrated that (131)I-CLR1404 significantly slowed the growth of malignant solid tumors and resulted in improved survival.

About Cellectar

Cellectar, Inc. is a clinical stage radiopharmaceutical company that designs, develops and manufactures products to detect, treat and monitor a wide variety of human cancers. Cellectar's novel product candidates combine lipid-like molecules, phospholipid ethers (PLEs) analogs, with radioisotopes that can either image or destroy malignant cells.  Cellectar's products' unique mechanism of action is based on their accumulation and selective retention in malignant tumors and not in normal cells. The company's operations are based in Madison, WI. For further information, please visit Cellectar's website at www.cellectar.com.

SOURCE Cellectar, Inc.

Back to top

RELATED LINKS
http://www.cellectar.com

'/>"/>

SOURCE Cellectar, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cellectar Expands Clinical Management Team
2. Chay Enterprises Inc. Completes Merger With Repurposed Drug Developer Ampio Pharmaceuticals, Inc.
3. Bacterin International Completes $3 Million Private Placement
4. Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round
5. Volcano Corporation Completes Acquisition of Lumen Biomedicals Xtract(TM) Thrombus Aspiration Catheter
6. Sanofi-aventis Successfully Completes Tender Offer for Chattem, Inc.
7. Valtech Cardio Ltd. Completes $17.8 Million in Series B Financing
8. SPO Medical Completes Restructuring Plan
9. Wound Management Technologies Completes Acquisition of Secure eHealth, LLC and Other Assets from VirtualHealth Technologies; Robert Tapales Appointed President of Secure eHealth, LLC
10. VirtualHealth Technologies Completes Sale of Secure eHealth, LLC and Other Assets to Wound Management Technologies; Robert Tapales Appointed President of Secure eHealth, LLC
11. Watson Completes Acquisition of Eden Biodesign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2017)... DIEGO , Aug. 3, 2017  Opioid addiction ... diseases driving up healthcare costs and threatening outcomes, were ... lab supply and IVD industry that support them, met ... care market researcher said that drugs of abuse, procalcitonin ... and sessions at the organization,s 69th meeting in ...
(Date:8/2/2017)... Aug. 2, 2017  Life Flight Network and PeaceHealth Oregon ... improves patient care and operational efficiency for patients at hospitals ... , Cottage Grove , and ... PeaceHealth and Life Flight Network work collaboratively to move patients ... or when a time sensitive emergency exists. ...
(Date:7/31/2017)... , July 31, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), ... Michigan by Crain,s Detroit Business ... and public companies by three-year revenue growth. This year,s edition ... To view the complete list, visit crainsdetroit.com/awards/fast_50/2017 ... is an incredible triumph," said Phil Hagerman , CEO ...
Breaking Medicine Technology:
(Date:8/22/2017)... ... August 22, 2017 , ... “Glimpses Of Light”: is a ... “Glimpses Of Light” is the creation of published author, J.M. Shepherd, a writer, teacher, ... answers to life’s perplexing mysteries. , Shepherd shares, “Love is one of the least ...
(Date:8/21/2017)... Louis, MO (PRWEB) , ... August 22, 2017 , ... ... career fairs to help healthcare employers connect with physicians and advanced practitioners like ... virtual career fairs in August through November of this year. The online ...
(Date:8/21/2017)... ... August 21, 2017 , ... SportsEngine, ... become the Official Technology Partner of North Country Region Volleyball and will power ... volleyball software, along with providing sport management software to their member clubs. ...
(Date:8/21/2017)... ... August 21, 2017 , ... PIXACORE , an independent full-service agency with ... 100 agencies of the year by MM&M. , This is the first time PIXACORE ... milestone for the agency. PIXACORE’s newfound recognition reflects its steady trajectory of growth ...
(Date:8/20/2017)... ... August 20, 2017 , ... A total solar eclipse will occur across ... minutes as the moon moves between the sun and Earth. This rare event will be ... tips can help keep you safe on the road during the total eclipse of the ...
Breaking Medicine News(10 mins):